About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
17
2020/03
Everest Medicines Forms Strategic Partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC
20
2020/02
Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer
15
2019/12
Everest Medicines Announces Approval of Nefecon's Clinical Trial Application by the China National Medical Products Administration
14
2019/11
Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
16
2019/09
Everest Medicines Expands Senior Leadership Team
10
2019/06
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore
09
2019/06
With Industry's Growing Kidney Moment, Everest Begins Building Kidney Portfolio
10
2019/05
Everest Medicines Appoints Wende Chen as Chief Commercial Officer
29
2019/04
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
07
2019/01
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
27
2018/08
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
25
2018/06
Everest Medicines Subsidiary Acquires Exclusive Worldwide License to Develop and Commercialize Clinical Stage Novel FGFR4 Kinase Inhibitor
<<
<
1
2
3
4
>
>>
Copyright Everest Medicines 2020
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
